0001209191-20-020483.txt : 20200320
0001209191-20-020483.hdr.sgml : 20200320
20200320170012
ACCESSION NUMBER: 0001209191-20-020483
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200319
FILED AS OF DATE: 20200320
DATE AS OF CHANGE: 20200320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DILLY STEPHEN GEORGE
CENTRAL INDEX KEY: 0001389147
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 20732665
MAIL ADDRESS:
STREET 1: C/O AVIGEN, INC.
STREET 2: 1301 HARBOR BAY PKWY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-19
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001389147
DILLY STEPHEN GEORGE
C/O SANGAMO THERAPEAUTICS, INC.
7000 MARINA BLVD.
BRISBANE
CA
94005
1
0
0
0
Common Stock
2020-03-19
4
M
0
35000
5.42
A
40000
D
Common Stock
2020-03-19
4
S
0
35000
6.00
D
5000
D
Stock Option (Right-to-Buy)
5.42
2020-03-19
4
M
0
35000
0.00
D
2020-03-30
Common Stock
35000
0
D
Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019.
The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.02 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.
/s/ Matthew Colvin, Attorney-in-Fact for Stephen G. Dilly
2020-03-20